Better Buy: Illumina vs. Exelixis

Jason Hawthorne, The Motley Fool
·5-min read
Better Buy: Illumina vs. Exelixis
Better Buy: Illumina vs. Exelixis

The latter is a scrappy biotech stock that has found ways to survive, despite setbacks, for more than 25 years. Regardless of previous success, investing is about the future. DNA sequencer products, like Illumina's, allow scientists to determine the information and instructions carried by a DNA sample.